GN Store Nord (GN) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
29 Nov, 2025Executive summary
Q1 2025 organic revenue declined by 3% year-over-year excluding wind-down, with total revenue at DKK 3,986 million, impacted by market uncertainty and U.S. tariffs.
EBITA dropped to DKK 300 million (margin 7.5%), reflecting negative operating leverage and launch costs.
Proactive mitigation actions include supply chain diversification, price increases, and cost containment to support margins and cash flow.
Strong product launches, notably ReSound Vivia, partially offset declines and drove market share gains.
Financial highlights
Revenue was DKK 3,986 million, with organic growth -8% (excluding wind-down: -3%).
Gross margin improved to 54.9% (up 2.0 p.p. year-over-year), despite negative business mix and tariffs.
EBITA was DKK 300 million (margin 7.5%, down 5.0 p.p. year-over-year).
Free cash flow excluding M&A was DKK -395 million, impacted by seasonality and higher interest and tax payments.
Adjusted leverage ended at 4.1x.
Outlook and guidance
2025 group organic revenue growth is guided at -3% to +3% (excluding wind-down).
EBITA/EBITDA margin guidance for 2025 is 11%-13%, assuming current tariff levels persist.
Free cash flow (excluding M&A) expected to be around DKK -800 million for the year.
Hearing division expected to deliver 5%-9% organic growth; Enterprise -8% to 0%; Gaming -6% to 2%.
Guidance reflects cautious optimism amid ongoing market and tariff uncertainty.
Latest events from GN Store Nord
- Hearing business sold to Amplifon for DKK 17B, enabling tech focus and global audiology leadership.GN
M&A announcement16 Mar 2026 - Guiding for 3%-7% organic growth and margin expansion in 2026, led by innovation and cost control.GN
Q4 20255 Feb 2026 - Pursuing margin expansion and growth through innovation in hearing, enterprise, and gaming.GN
SEB Nordic Seminar presentation5 Feb 2026 - 5% organic growth and margin gains, with strong Hearing and Gaming, guidance confirmed.GN
Q2 202423 Jan 2026 - Record cash flow and margin gains as Hearing outperformed, offsetting mixed divisional growth.GN
Q3 202416 Jan 2026 - Strong EBITDA growth, new board members, and strategic focus on innovation and resilience.GN
AGM 202520 Dec 2025 - Strong 2024 growth and margin gains set the stage for further expansion in 2025.GN
Q4 202417 Dec 2025 - EBITA up 46% on margin gains, with Hearing strong and 2025 guidance narrowed amid tariff risks.GN
Q2 202523 Nov 2025 - Q3 2025 saw 1% organic growth, 11% EBITA margin, and strong cash flow, led by Hearing.GN
Q3 202513 Nov 2025